Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) was upgraded by equities researchers at RODMAN&RENSHAW to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.
Other research analysts also recently issued research reports about the company. Rodman & Renshaw began coverage on Cardiol Therapeutics in a research note on Tuesday. They set a “buy” rating and a $7.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a research note on Wednesday, December 18th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $8.40.
View Our Latest Stock Report on Cardiol Therapeutics
Cardiol Therapeutics Price Performance
Hedge Funds Weigh In On Cardiol Therapeutics
Several large investors have recently modified their holdings of the business. Foundations Investment Advisors LLC increased its holdings in Cardiol Therapeutics by 237.4% in the third quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company’s stock valued at $321,000 after purchasing an additional 113,950 shares during the period. Lion Street Advisors LLC raised its position in shares of Cardiol Therapeutics by 12.6% during the fourth quarter. Lion Street Advisors LLC now owns 307,666 shares of the company’s stock worth $396,000 after acquiring an additional 34,385 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Cardiol Therapeutics in the third quarter worth approximately $29,000. Townsquare Capital LLC bought a new stake in Cardiol Therapeutics in the third quarter valued at approximately $27,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Cardiol Therapeutics during the 3rd quarter valued at approximately $27,000. Institutional investors own 12.49% of the company’s stock.
About Cardiol Therapeutics
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
- Five stocks we like better than Cardiol Therapeutics
- Election Stocks: How Elections Affect the Stock Market
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Using the MarketBeat Dividend Yield Calculator
- 3 Steel Stocks Soaring After Tariff Announcements
- What is the Euro STOXX 50 Index?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.